Which has higher earnings & valuation, KYMR or BIIB?

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 228.01 -$311.35M -$3.57 N/A Biogen $9.89B 3.11 $1.29B $5.65 36.80

Does the media refer more to KYMR or BIIB?

In the previous week, Kymera Therapeutics had 3 more articles in the media than Biogen. MarketBeat recorded 27 mentions for Kymera Therapeutics and 24 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat Kymera Therapeutics' score of 0.08 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 14 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYMR or ALNY?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 39 mentions for Alnylam Pharmaceuticals and 27 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.08 beat Alnylam Pharmaceuticals' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 6 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KYMR or ROIV?

In the previous week, Kymera Therapeutics had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 27 mentions for Kymera Therapeutics and 20 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.06 beat Kymera Therapeutics' score of 0.08 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 12 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, INCY or KYMR?

Incyte has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.75 $1.29B $7.85 15.36 Kymera Therapeutics $39.21M 228.01 -$311.35M -$3.57 N/A

Is INCY or KYMR more profitable?

Incyte has a net margin of 27.71% compared to Kymera Therapeutics' net margin of -285.33%. Incyte's return on equity of 29.93% beat Kymera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Kymera Therapeutics -285.33% -21.82% -19.66%

Does the media prefer INCY or KYMR?

In the previous week, Kymera Therapeutics had 11 more articles in the media than Incyte. MarketBeat recorded 27 mentions for Kymera Therapeutics and 16 mentions for Incyte. Incyte's average media sentiment score of 0.83 beat Kymera Therapeutics' score of 0.08 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KYMR or BNTX?

In the previous week, Kymera Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 27 mentions for Kymera Therapeutics and 26 mentions for BioNTech. Kymera Therapeutics' average media sentiment score of 0.08 beat BioNTech's score of -0.25 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Kymera Therapeutics (KYMR) Competitors

$107.52 +1.11 (+1.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$107.46 -0.06 (-0.06%)

As of 08/7/2026 07:34 PM Eastern

Compare

KYMR vs. BIIB, ALNY, ROIV, INCY, and BNTX

Should you buy Kymera Therapeutics stock or one of its competitors? MarketBeat compares Kymera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kymera Therapeutics include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), Incyte (INCY), and BioNTech (BNTX). These companies are all part of the "biotechnology" industry.

How does Kymera Therapeutics compare to Biogen?

Kymera Therapeutics (NASDAQ:KYMR) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Biogen has a net margin of 8.32% compared to Kymera Therapeutics' net margin of -285.33%. Biogen's return on equity of 11.18% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	228.01	-$311.35M	-$3.57	N/A
Biogen	$9.89B	3.11	$1.29B	$5.65	36.80

Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $125.65, indicating a potential upside of 16.86%. Biogen has a consensus target price of $224.61, indicating a potential upside of 8.02%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kymera Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Kymera Therapeutics had 3 more articles in the media than Biogen. MarketBeat recorded 27 mentions for Kymera Therapeutics and 24 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat Kymera Therapeutics' score of 0.08 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	14 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Kymera Therapeutics (NASDAQ:KYMR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Alnylam Pharmaceuticals has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	228.01	-$311.35M	-$3.57	N/A
Alnylam Pharmaceuticals	$3.71B	7.90	$313.75M	$5.38	40.74

Kymera Therapeutics presently has a consensus price target of $125.65, suggesting a potential upside of 16.86%. Alnylam Pharmaceuticals has a consensus price target of $396.72, suggesting a potential upside of 80.98%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Kymera Therapeutics' net margin of -285.33%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 39 mentions for Alnylam Pharmaceuticals and 27 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.08 beat Alnylam Pharmaceuticals' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	6 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Kymera Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Kymera Therapeutics (NASDAQ:KYMR) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Roivant Sciences has lower revenue, but higher earnings than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	228.01	-$311.35M	-$3.57	N/A
Roivant Sciences	$8.26M	3,164.44	-$299.77M	-$0.60	N/A

Kymera Therapeutics currently has a consensus price target of $125.65, suggesting a potential upside of 16.86%. Roivant Sciences has a consensus price target of $34.77, suggesting a potential downside of 4.31%. Given Kymera Therapeutics' higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Kymera Therapeutics has a net margin of -285.33% compared to Roivant Sciences' net margin of -3,534.96%. Kymera Therapeutics' return on equity of -21.82% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Kymera Therapeutics had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 27 mentions for Kymera Therapeutics and 20 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.06 beat Kymera Therapeutics' score of 0.08 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	12 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Incyte currently has a consensus price target of $120.40, indicating a potential downside of 0.13%. Kymera Therapeutics has a consensus price target of $125.65, indicating a potential upside of 16.86%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

97.0% of Incyte shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 11 more articles in the media than Incyte. MarketBeat recorded 27 mentions for Kymera Therapeutics and 16 mentions for Incyte. Incyte's average media sentiment score of 0.83 beat Kymera Therapeutics' score of 0.08 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Incyte has a net margin of 27.71% compared to Kymera Therapeutics' net margin of -285.33%. Incyte's return on equity of 29.93% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Kymera Therapeutics	-285.33%	-21.82%	-19.66%

Incyte has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.75	$1.29B	$7.85	15.36
Kymera Therapeutics	$39.21M	228.01	-$311.35M	-$3.57	N/A

Summary

Incyte beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to BioNTech?

Kymera Therapeutics (NASDAQ:KYMR) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Kymera Therapeutics currently has a consensus target price of $125.65, suggesting a potential upside of 16.86%. BioNTech has a consensus target price of $127.81, suggesting a potential upside of 36.45%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

15.5% of BioNTech shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 1 more articles in the media than BioNTech. MarketBeat recorded 27 mentions for Kymera Therapeutics and 26 mentions for BioNTech. Kymera Therapeutics' average media sentiment score of 0.08 beat BioNTech's score of -0.25 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a net margin of -63.54% compared to Kymera Therapeutics' net margin of -285.33%. BioNTech's return on equity of -6.86% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.82%	-19.66%
BioNTech	-63.54%	-6.86%	-6.00%

Kymera Therapeutics has higher earnings, but lower revenue than BioNTech. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	228.01	-$311.35M	-$3.57	N/A
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A

Summary

BioNTech beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.94B	$3.70B	$7.03B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-33.19	9.02	271.36	25.17
Price / Sales	228.01	1,303.67	600.88	88.07
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	5.54	18.10	13.25	6.22
Net Income	-$311.35M	-$13.25M	$3.45B	$342.66M
7 Day Performance	3.98%	6.24%	4.67%	4.41%
1 Month Performance	-5.82%	-2.70%	-0.79%	-0.28%
1 Year Performance	164.70%	61.17%	76.94%	22.60%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	1.8637 of 5 stars	$107.52 +1.0%	$125.65 +16.9%	+163.2%	$8.94B	$39.21M	N/A	170	Trending News Earnings Report Analyst Forecast Analyst Revision
BIIB Biogen	3.9073 of 5 stars	$204.55 +1.4%	$223.89 +9.5%	+62.8%	$30.20B	$9.89B	36.18	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.7846 of 5 stars	$216.51 -1.7%	$401.24 +85.3%	-49.6%	$28.97B	$3.71B	40.25	2,770	Trending News Analyst Forecast Analyst Revision
ROIV Roivant Sciences	1.6242 of 5 stars	$34.23 +2.7%	$33.59 -1.9%	+214.6%	$24.57B	$8.26M	N/A	860	Trending News Analyst Forecast
INCY Incyte	3.558 of 5 stars	$118.88 +0.4%	$119.60 +0.6%	+54.2%	$24.10B	$5.14B	15.14	2,844	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, ROIV, INCY, and BNTX

How does Kymera Therapeutics compare to Biogen?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Summary

How does Kymera Therapeutics compare to Incyte?

Summary

How does Kymera Therapeutics compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. BIIB, ALNY, ROIV, INCY, and BNTX

How does Kymera Therapeutics compare to Biogen?

Is KYMR or BIIB more profitable?

Which has higher earnings & valuation, KYMR or BIIB?

Which has more volatility & risk, KYMR or BIIB?

Do analysts rate KYMR or BIIB?

Does the media refer more to KYMR or BIIB?

Do insiders & institutionals hold more shares of KYMR or BIIB?

Summary

How does Kymera Therapeutics compare to Alnylam Pharmaceuticals?

Which has higher valuation & earnings, KYMR or ALNY?

Do analysts recommend KYMR or ALNY?

Is KYMR or ALNY more profitable?

Which has more risk & volatility, KYMR or ALNY?

Do insiders & institutionals hold more shares of KYMR or ALNY?

Does the media refer more to KYMR or ALNY?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Which has better valuation and earnings, KYMR or ROIV?

Do analysts rate KYMR or ROIV?

Is KYMR or ROIV more profitable?

Which has more risk and volatility, KYMR or ROIV?

Do insiders & institutionals hold more shares of KYMR or ROIV?

Does the media favor KYMR or ROIV?

Summary

How does Kymera Therapeutics compare to Incyte?

Do analysts recommend INCY or KYMR?

Do institutionals & insiders believe in INCY or KYMR?

Which has more risk and volatility, INCY or KYMR?

Does the media prefer INCY or KYMR?

Is INCY or KYMR more profitable?

Which has higher earnings & valuation, INCY or KYMR?

Summary

How does Kymera Therapeutics compare to BioNTech?

Do analysts recommend KYMR or BNTX?

Do institutionals & insiders have more ownership in KYMR or BNTX?

Which has more volatility and risk, KYMR or BNTX?

Does the media favor KYMR or BNTX?

Is KYMR or BNTX more profitable?

Which has higher valuation and earnings, KYMR or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools